Guardant Health, Inc. (NASDAQ:GH) Shares Sold by First Trust Advisors LP

First Trust Advisors LP cut its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 47.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,723 shares of the company's stock after selling 50,951 shares during the period. First Trust Advisors LP's holdings in Guardant Health were worth $1,733,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Guyasuta Investment Advisors Inc. purchased a new position in shares of Guardant Health during the fourth quarter worth $206,000. Entropy Technologies LP acquired a new position in shares of Guardant Health in the 4th quarter valued at about $377,000. Raymond James Financial Inc. acquired a new position in shares of Guardant Health in the 4th quarter valued at about $2,211,000. Swiss National Bank grew its holdings in Guardant Health by 1.0% during the fourth quarter. Swiss National Bank now owns 241,900 shares of the company's stock worth $7,390,000 after acquiring an additional 2,500 shares during the period. Finally, Rhumbline Advisers raised its position in Guardant Health by 2.2% during the fourth quarter. Rhumbline Advisers now owns 167,230 shares of the company's stock valued at $5,109,000 after acquiring an additional 3,529 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Trading Up 0.1 %

GH stock traded up $0.04 during trading on Friday, reaching $41.72. 2,781,560 shares of the stock were exchanged, compared to its average volume of 2,231,424. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of -11.72 and a beta of 1.49. The business has a 50 day moving average price of $43.72 and a 200-day moving average price of $38.69. Guardant Health, Inc. has a 1 year low of $18.01 and a 1 year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm's quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.46) earnings per share. On average, research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GH shares. Morgan Stanley boosted their target price on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. UBS Group raised their target price on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a report on Monday. Mizuho began coverage on Guardant Health in a report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price objective on the stock. Finally, Raymond James reaffirmed an "outperform" rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Twenty-one research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $52.32.

Insider Buying and Selling

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at $107,952,954.72. This represents a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 107,132 shares of company stock valued at $5,249,355. 5.50% of the stock is currently owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.